News & Announcements

Catalyst Group Launches Catinox: Specialist Surface Technology Division for Life Sciences

LIESTAL, SWITZERLAND - Catalyst Group AG is pleased to announce the official launch of Catinox, its dedicated surface treatment division serving pharmaceutical and biotechnology clients.

Catinox delivers engineer-led, GMP-compliant surface treatment for pharmaceutical and biotech process systems: on-site for fixed installations (water-for-injection loops, clean-steam systems, process skids) and in-house for components, fittings, and small parts. Services span the full surface treatment lifecycle: rouge assessment and classification (Type I, II, III), chemical derouge using pH-neutral chemistry, repassivation, CIP cleaning, descaling, derusting, and ultrasonic cleaning. Every treatment cycle is documented to validation-grade standard, supported by ISO 9001:2015 and ISO 14001:2015 certification.

The division was built around a compliance program model rather than a one-off service: establishing a system baseline, supporting risk-based monitoring, and treating on schedule before rouge becomes a deviation or an inspection finding. This approach reflects the team's background: Catinox engineers have specified, designed, and commissioned the same GMP systems they now service, which means they understand precisely what quality teams need, because they used to be on that side of the table.

The integration of Catinox within Catalyst Group means clients gain access to specialist surface treatment capabilities as part of a broader project management, commissioning, and qualification program, delivered by a single accountable partner across the full facility lifecycle. For more information, visit www.catinox.ch.

Learn about Catinox

Catalyst Group Converts to AG: Strengthening Structure for Long-Term Growth

LIESTAL, SWITZERLAND - Catalyst Group has officially converted its legal structure from a limited liability company (GmbH) to a Swiss stock corporation (Aktiengesellschaft / AG), now operating as Catalyst Group AG.

This structural change reflects the company's continued growth and its commitment to building a durable, scalable organisation capable of taking on larger mandates, deepening its partnership ecosystem, and expanding across the EMEA region. The AG structure also supports greater transparency, governance, and alignment with the expectations of institutional and multinational clients in the life sciences and AEC sectors.

All existing client relationships, agreements, and obligations continue without interruption. The company is registered in the Canton of Basel-Landschaft, with its registered office at Industriestrasse 7, 4410 Liestal, Switzerland.

Get in touch

Catalyst Group and N+1 Process Engineering Solutions Announce Strategic Partnership to Drive Innovation in Life Sciences and Advanced Technologies

BASEL, SWITZERLAND - Catalyst Group is proud to announce a strategic partnership with N+1 Process Engineering Solutions, a US-based provider of cutting-edge process engineering solutions. This collaboration marks a significant step in expanding N+1's footprint into the EMEA region while jointly driving the development of innovative and disruptive technologies for the Life Science and Advanced Technology Industries.

With a shared vision of transforming biopharmaceutical manufacturing, the partnership focuses on bringing N+1's current product portfolio to the EMEA market and co-developing next-generation solutions aimed at reducing costs, enhancing sustainability, and optimising facility design. By leveraging Catalyst Group's deep expertise in the European market and N+1's strong technological capabilities, the alliance is set to introduce breakthrough solutions that alleviate the challenges the industry is facing.

"This partnership is a natural fit for both companies, combining Catalyst Group's established network with N+1's advanced process engineering innovations. Together, we will challenge industry norms, accelerate technological advancements, and address ongoing challenges that clients are facing in Life Science and Advanced Technology Industries."

N+1's CEO, Robert Hendrix-Ojeda, added: "Expanding into the EMEA region with a trusted partner like Catalyst Group allows us to bring our solutions to a broader market. This partnership additionally allows N+1 to leverage Catalyst Group's unique skill set to provide co-developed innovative technologies to further accelerate our customers' pathways toward sustainable biopharmaceutical manufacturing."

This collaboration underscores both companies' commitment to creating scalable, high-impact solutions that address the evolving needs of the industry, focusing on disruptive technologies that optimise operations, derisk pathways to innovation, and enhance sustainability.

Contact us for more information